Skip to main content

Advertisement

Table 3 In vitro effect of AMP + Tobramycin (TOB) combinations against P. aeruginosa , S. maltophilia , and S. aureus CF strains

From: Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

Drug combinations P. aeruginosa S. maltophilia S. aureus
Synergy Indifference Antagonism Synergy Indifference Antagonism Synergy Indifference Antagonism
FICIa≤ 0.5 0.5 < FICI ≤ 4 FICI > 4 FICI ≤ 0.5 0.5 < FICI ≤ 4 FICI > 4 FICI ≤ 0.5 0.5 < FICI ≤ 4 FICI > 4
BMAP-27 + TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%) 8 (100%) 0 (0%) 1 (100%)b 0 (0%)b 0 (0%)b
BMAP-28 + TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%) 8 (100%) 0 (0%) 0 (0%)c 1 (100%)c 0 (0%)c
P19(9/B) + TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%) 8 (100%) 0 (0%) 1 (33.3%)d 2 (66.7%)d 0 (0%)d
  1. a Fractional Inhibitory Concentration Index (FICI).
  2. Only isolates exhibiting in-range MIC values were considered for checkerboard titration method: P. aeruginosa (n = 12), S. maltophilia (n = 8), and S. aureus (b n = 1; c n = 1; d n = 3).